logo
MerckAnnouncesFirstDoseinPhase3StudywithEnpatoranforLupusPatientswithActiveSkinManifestations
===2026/5/6 9:43:48===
: April 2026.





6Kandane-Rathnayake, Louthrenoo W, Hoi A, et al. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. Arthritis Res Ther. 2022;24:70.
















Contacts


Media Relations
flavia.felix@emdserono.com
Phone: +1 781 427 1892



David Weinreich, Global Head of R&D and Chief Medical Officer
=*=*=*=*=*=
当前为第10/10页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页